Chemed Q2 revenue up 4.2% to $554M; adjusted EPS $4.71 down 2.7% YoY

CHEMED CORP

2023-Q2 EPS reported $7.09 revenue$1,113,973,000

GAAP diluted EPS $3.51; adjusted diluted EPS $4.71 (down 2.7% YoY).
VITAS net revenue $321M (+7.8%); ADC 18,392 (+6.2%); admissions 15,611 (+5.9%).
Roto-Rooter revenue $233M (-0.2%); adjusted EBITDA $65.9M (-4.5%); margin 28.3%.
No debt; $160M cash; $405M undrawn credit facility; repurchased 25,000 shares for $13.4M.
FY2023 adjusted EPS guidance $19.90-$20.10 vs 2022's $19.75.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CHEMED CORP reported second quarter ended June 30, 2023 results: revenue $554 million, EPS $3.51. Guidance reaffirmed.

Period: second quarter ended June 30, 2023
Revenue: $554 million
EPS: $3.51
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Chemed Corporation (Chemed) (NYSE: CHE ), which operates VITAS Healthcare Corporation (VITAS), one of the nation’s largest providers of end-of-life care, and Roto-Rooter, the nation’s largest commercial and residential plumbing and drain cleaning services provider, reported financial results for its second quarter ended June 30, 2023, versus the comparable prior-year period, as follows: Consolidated operating results: · Revenue increased 4.2% to $554 million · GAAP Diluted Earnings-per-Share (EPS) of $3.51 · Adjusted Diluted EPS of $4.71, a decrease of 2.7%

View on SEC.gov

Browse all earnings releases →

CHEMED CORP filing history →

Source: SEC EDGAR

accession 0001562762-23-000290

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.